These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11927094)

  • 1. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
    Danés Carreras I; Arnau De Bolós JM
    An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X; Quero Jiménez J
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
    Robinson JL
    Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
    [No Abstract]   [Full Text] [Related]  

  • 7. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Respiratory syncytial virus infections and preventive options].
    Moll HA; de Groot R
    Ned Tijdschr Geneeskd; 2000 Apr; 144(15):724-5. PubMed ID: 10778722
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 10. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Speer ME; Fernandes CJ; Boron M; Groothuis JR
    Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
    Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
    Parnes C; Guillermin J; Habersang R; Nicholes P; Chawla V; Kelly T; Fishbein J; McRae P; Goessler M; Gatti A; Calcagno JA; Eki C; Harris KA; Joyave J; McFarland K; Protter P; Sullivan M; Stanford A; Lovett N; Ortiz M; Rojas S; Cyrus S; Cyrus J; Cohen S; Buchin D; Riordan L; Zuniga M; Shah R; Minard C; Quintin A; Douglas G; van Houten J; Freutner S; Chartrand S; Nowatzke P; Romero J; Rhodes T; Benoit M; Walter E; Walker L; DeBonnett L; Cross M; Free T; Martin S; Shank K; Guedes B; Atkinson LA; Halpin GJ; Rouse K; Hand I; Geiss D; Marshall JR; Burleson L; Boland J; Seybold K; Hunter V; Unfer S; Schmucker J; Gley M; Marcus M; Thompson P; Milla P; Young C; Zanni R; Zinno V; Fetter-Zarzeka A; Busey A; Sokunbi MA; Airington S; Richard N; Muraligopal V; Lewis S; Weber FT; Giordano BP; Linehan D; Roach J; Davis R; Rzepka AA; Booth T; Smeltzer D; Walsh J; Arispe E; Rowley R; Bolling C; Botts T; Haskett K; Raby D; Batiz E; Gelfand A; Farrell L; Butler S; Colby L; Schochet P; Bentler J; Hirsch D; Wilkinson L; Aaronson A; Bennett E; Wingate J; Quinn D; Komendowski K; Deckard M; Frogel M; Nerwen C; Copenhaver S; Prater M; Wolsztein J; Mackey K; Benbow M; Naranjo M; Hensley S; Hayes C; Sadeghi H; Lawson SM; McCall M; Combs K; Ledbetter J; Sarnosky K; Swafford C; Speer M; Barton WJ; Mink JW; Lemm D; Hudak M; Case E; Rowen J; Fuentes S; Pane C; Richardson L; Chavarria C; Cassino D; Ghaffari K; Carroll C; Lee H; Guclu L; Johnson C; Blum V; Boron ML; Sorrentino M; Hirsch RL; Van Veldhuisen PC; Smith C;
    Pediatr Pulmonol; 2003 Jun; 35(6):484-9. PubMed ID: 12746948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
    J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.